← Signals · Healthcare · TSXV
$TLT
Theralase Technologies Inc.
Signal as of N/A  ·  90-day rolling window  ·  Medical Equipment & Supplies
Confluence Score
out of 100  ·  Full breakdown →
Score delayed 7 days on Free  ·  See today's score — Analyst →
Signals scoring 20–39 have historically hit 47% of the time (avg +6.8% over 90 days, 105 backtested signals). Methodology →
🔒 Risk monitoring — insider-selling & reversal warnings (Analyst)
⚡ First insider buying in 28 months
Confluence Score
Insider Activity (90d)
2
1 buyer  ·  $10K  ·  open-market only
Current Price
$0.26
CAD  ·  5-min cache
Market Cap
$67M
CAD  ·  TMX
Lobbying & Contracts
None
0 regs  ·  0 contracts
Healthcare on Form55: 43% hit rate · -5.4% alpha vs XIU.TO · 21 closed signals Track Record →
Signal Analyst
The Confluence Score and insider trade feed above are free. Signal Analyst adds the full component breakdown, lobbying registrations, and contract wins — plus alerts when this company's signal moves, so you don't have to keep checking back.
Monitor — CAD $29/mo
Price Chart
12 months daily  ·  TSXV:TLT
Insider Transactions
90-day window  ·  13 filings
Date Insider Role Nature Dir. Shares Buy Price Return Value
May 20, 2026 Bruder, Randall Open Market Buy 20,900 $0.24 +8.3%  · 52d $5K
May 20, 2026 Bruder, Randall Open Market Sell 20,900 $0.32 $7K
May 20, 2026 Bruder, Randall Open Market Sell 20,900 $0.24 $5K
May 20, 2026 Bruder, Randall Open Market Sell 20,900 $0.24 $5K
May 20, 2026 Bruder, Randall Open Market Buy 20,900 $0.24 +8.3%  · 52d $5K
May 20, 2026 Hachey, Kristina Maria Open Market Sell 11,000 $0.24 $3K
May 20, 2026 Hachey, Kristina Maria Comp. Grant Buy 11,000 $0.32 -18.8%  · 52d $4K
May 20, 2026 Mandel, Arkady Open Market Sell 11,000 $0.24 $3K
May 20, 2026 Mandel, Arkady Comp. Grant Buy 11,000 $0.32 -18.8%  · 52d $4K
May 20, 2026 Dumoulin-White, Roger John Open Market Sell 25,000 $0.24 $6K
May 20, 2026 Dumoulin-White, Roger John Comp. Grant Buy 25,000 $0.32 -18.8%  · 52d $8K
May 20, 2026 Perraton, Matthew Thomas Open Market Sell 11,000 $0.24 $3K
May 20, 2026 Perraton, Matthew Thomas Open Market Sell 11,000
Score uses open-market buys only  ·  2 open-market  ·  3 plan / compensation shown but not scored  ·  Return is unrealized, to today's price; a “· Nd” mark means the 90-day window is still open (N of 90 days) — too early to judge.
Score Breakdown
Signal Analyst  ·  $29/mo
Component Points Max Detail Weight
Conviction (unique buyers)  ✓ FREE PREVIEW 30 30 1 unique buyer (maximum conviction)
Buy/sell ratio 20 20% buys (2B / 8S)
Dollar value 25 $10K
Lobbying activity 15 None
Contract wins 10 None
Insider track record 10 No track record data
Private placements 8 None
Confluence bonus 10 None
Cluster timing (velocity) 10 No coordinated buying cluster detected
Buy/sell reversal pattern 8 No buy/sell reversal pattern
Total 0 100
Unlock Component Detail — CAD $29/mo
Buying Insiders
Open-market · 90 days · 1 unique buyer
Insider Credibility Hit Rate Avg 90d Return Trades (eval'd) Buy Value (90d) Last Buy
Bruder, Randall $10K May 20, 2026
Credibility score: historical hit rate × avg 90d return × sample size. View full insider leaderboard →
Lobbying Registrations
OCL active  ·  none found
No active OCL lobbying registrations in the last 90 days. Analyst plan →
Government Contract Wins
90-day window  ·  none found
No government contract wins in the last 90 days. Analyst plan →
Private Placements
12 months  ·  Signal Analyst  ·  $29/mo
Private placement history, deal size, and lock-up expiry tracking. Analyst plan →
Indigenous Consultation
no records on file

No Indigenous consultation records on file for TLT.

SEDAR+ Filings
official filing registry
Form55 monitors SEDAR+ filing alerts and newswire announcements for Technical Reports and material changes. Search SEDAR+ →
Short Interest
CIRO  ·  Jun 30, 2026
Shares short
20,302
Net change
+10,859 (+115.0%)
Short interest rose 115% since the prior report.
History
Jun 30: 20,302
Jun 15: 9,443
May 31: 63,531
May 15: 5,686,154
Apr 30: 1,746,332
Aggregate short position from CIRO's Consolidated Short Position Report (published twice monthly).
Clinical Trials
ClinicalTrials.gov  ·  2 trials
Phase Status Trial Updated
P2 Recruiting Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolera Nov 2025
P1 Completed Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk No Aug 2018
Trials where this company is the lead sponsor (ClinicalTrials.gov). Phase advances, completions and terminations are material catalysts for clinical-stage companies — not investment advice.
Form55 provides data and analysis for informational purposes only. Nothing on this site constitutes investment advice or a recommendation to buy or sell any security. Past performance is not indicative of future results.